Direkt zum Inhalt
Merck

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.

Oncotarget (2015-07-15)
Rajani Rajbhandari, Braden C McFarland, Ashish Patel, Magda Gerigk, G Kenneth Gray, Samuel C Fehling, Markus Bredel, Nicolas F Berbari, Hyunsoo Kim, Margaret P Marks, Gordon P Meares, Tanvi Sinha, Jeffrey Chuang, Etty N Benveniste, Susan E Nozell
ZUSAMMENFASSUNG

Glioblastomas (GBMs) are deadly tumors of the central nervous system. Most GBM exhibit homozygous deletions of the CDKN2A and CDKN2B tumor suppressors at 9p21.3, although loss of CDKN2A/B alone is insufficient to drive gliomagenesis. MIR31HG, which encodes microRNA-31 (miR-31), is a novel non-coding tumor suppressor positioned adjacent to CDKN2A/B at 9p21.3. We have determined that miR-31 expression is compromised in >72% of all GBM, and for patients, this predicts significantly shortened survival times independent of CDKN2A/B status. We show that miR-31 inhibits NF-κB signaling by targeting TRADD, its upstream activator. Moreover, upon reintroduction, miR-31 significantly reduces tumor burden and lengthens survival times in animal models. As such, our work identifies loss of miR-31 as a novel non-coding tumor-driving event in GBM.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
IFN-alpha 1 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)